Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 12,464 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cell Therapy Clear all
Completed Phase 3 Interventional

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past

NCT00002320
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
12 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • Sherman Oaks, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2005 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

NCT00258323
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, fluorouracil, Iressa, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 23, 2026, 6:09 PM EDT
Recruiting Phase 2 Interventional

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

NCT03970096
View directory record Official record
Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Total-Body Irradiation, Thiotepa, Fludarabine, Tacrolimus, Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Methotrexate, Cyclophosphamide, Peripheral Blood Stem Cell, Cyclosporine, Sirolimus, Busulfan, Bone Marrow Aspiration and Biopsy, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection
Radiation · Drug · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
3
States / cities
Tampa, Florida • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Not applicable Interventional

Evaluation of Bilayered Cellular Matrix (OrCel) for the Treatment of Venous Ulcers

NCT00270946
View directory record Official record
Conditions
Venous Leg Ulcer, Venous Stasis Ulcer
Interventions
Bilayered Cellular Matrix (OrCel)
Device
Lead sponsor
Ortec International
Industry
Eligibility
18 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Montgomery, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 29, 2005 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

NCT02107235
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
oral rigosertib, cisplatin, Radiotherapy
Drug · Radiation
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Aurora, Colorado • Newark, Delaware • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 23, 2026, 6:09 PM EDT
Terminated Phase 3 Interventional Results available

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

NCT00480025
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
GSK1572932A Antigen-Specific Cancer Immunotherapeutic, Placebo Control
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 157 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3

NCT00000625
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 23, 2026, 6:09 PM EDT
Recruiting Phase 2 Interventional

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

NCT00107289
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma
Interventions
iobenguane I 131
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
Withdrawn Phase 2 Interventional

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

NCT05935774
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Atezolizumab, Biopsy, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Trabedersen (OT-101)
Biological · Procedure · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)

NCT01002924
View directory record Official record
Conditions
Solid Tumors
Interventions
EC145
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 23, 2026, 6:09 PM EDT
Terminated Phase 1 Interventional

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

NCT00971191
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
PF-00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

NCT04965597
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
Interventions
Treosulfan, Fludarabine Phosphate, Tacrolimus, Methotrexate, Lapine T-Lymphocyte Immune Globulin, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Quality-of-Life Assessment, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, X-Ray Imaging, Computed Tomography
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 49 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
Terminated Phase 1 Interventional

Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00033423
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, yttrium Y 90 ibritumomab tiuxetan
Biological · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
3
States / cities
Birmingham, Alabama • Stanford, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

NCT02485535
View directory record Official record
Conditions
Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Laboratory Biomarker Analysis, Selinexor
Other · Drug
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 2 Interventional Results available

A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

NCT00077974
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
SU011248
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
15
States / cities
Duarte, California • Pasadena, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer

NCT00004190
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
18
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 4 Interventional Results available

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

NCT02713997
View directory record Official record
Conditions
Pancreatitis, Chronic; Diabetes; Transplant
Interventions
etanercept, Alpha 1-Antitrypsin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

NCT00962260
View directory record Official record
Conditions
Gaucher Disease
Interventions
Plant cell expressed recombinant glucocerebrosidase (prGCD)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
U.S. locations
14
States / cities
La Jolla, California • Aurora, Colorado • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Not applicable Interventional

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

NCT00749320
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Arterial Spin Labeling Magnetic Resonance Imaging
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 23, 2026, 6:09 PM EDT
Recruiting Phase 1 Interventional

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

NCT07565220
View directory record Official record
Conditions
Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Leukemia, Myelodysplastic Syndrome(MDS), Myeloproliferative Neoplasm (MPN)
Interventions
Thiotepa, Fludarabine, Busulfan, PBSC infusion
Drug · Procedure
Lead sponsor
Sawa Ito, MD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

NCT04315324
View directory record Official record
Conditions
Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma, T Lymphoblastic Lymphoma
Interventions
AKR1C3-activated Prodrug AST-3424, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
12 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
163
States / cities
Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Not applicable Interventional

A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell

NCT00002323
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Oakland, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 6:09 PM EDT
Recruiting Not applicable Interventional

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients

NCT06615635
View directory record Official record
Conditions
Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised, Carcinoma, Squamous, Skin Cancer, Brachytherapy
Interventions
DaRT seeds
Device
Lead sponsor
Alpha Tau Medical LTD.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
10
States / cities
Gilbert, Arizona • Phoenix, Arizona • Boca Raton, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
Completed No phase listed Observational

Culture of Circulating Tumor Cells Isolated From Cancer Patients With Metastatic Disease

NCT02781025
View directory record Official record
Conditions
Circulating Tumor Cells
Interventions
Blood draw
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 23, 2026, 6:09 PM EDT